Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

High Dose Chemotherapy Followed By PBSC Rescue for HD

This study has been completed.
Information provided by:
Stanford University Identifier:
First received: September 13, 2005
Last updated: November 9, 2012
Last verified: July 2012
To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.

Condition Intervention
Hodgkin Disease
Procedure: high dose chemo then auto hematopoietic cell transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Overall survival
  • FFS
  • Response rates

Secondary Outcome Measures:
  • Toxicity of high dose chemotherapy

Estimated Enrollment: 200
Study Start Date: March 1998
Estimated Study Completion Date: July 2005
Detailed Description:
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Ages Eligible for Study:   up to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:- adequate organ function

  • recurrent HD Exclusion Criteria:- CNS disease
  • no prior malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00186251

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Sally Arai Stanford University
  More Information Identifier: NCT00186251     History of Changes
Other Study ID Numbers: BMT24
13322 ( Other Identifier: Stanford IRB )
Study First Received: September 13, 2005
Last Updated: November 9, 2012

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on May 25, 2017